Table 2.

Summary of Key Trials Related to PD-1/PD-L1 Inhibitors in Ovarian Cancer.

Study	Design	Population	Experimental arm	ORR (%)	PFS (months)	OS (months)	Reference
KEYNOTE-100	Open-label, single arm, phase II trial	PROC N=376	Pembrolizumab	8.0	2.1	17.6	(242)
JAVELIN 100	Randomized, open-label, phase III trial	Treatment naïve OC N=998	CPT Maintenance Avelumab	30	16.8 (HR=1.43)	NE	(17)
			CPT + avelumab Maintenance Avelumab	36	18.1 (HR=1.14)	NE
JAVELIN 200	Randomized, open-label, phase III trial	PROC N=566	Avelumab	4	1.9 (HR=1.68)	11.8 (HR=1.14)	(16)
			Avelumab + PLD	13	3.7 (HR=0.78)	15.7 (HR=0.89)
IMagyn050	Randomized, double-blind, phase III trial	Treatment naïve OC N=1301	CPT + bevacizumab + atezolizumab	NA	19.5 (HR=0.92) PDL1 + 20.8 (HR=0.80)	NE PDL1+ NE	(15)
ATALANTE	Randomized, double-blind, phase III trial	PSROC <2 prior lines N=1301	Carboplatin doublet + bevacizumab + atezolizumab	NA	13.5 (HR=0.83) PDL1 + 15.2 (HR=0.86)	35.5 (HR=0.81)	(14)
NINJA	Randomized, open-label, phase III trial	PROC N=363	Nivolumab	7.6	2.0 (HR=1.5)	10.1 (HR=1.03)	(244)
NRG GY003	Randomized, open-label, phase II trial	Relapsed OC N=100	Nivolumab + Ipilimumab	6-month ORR 31.4	3.9 (HR=0.53)	28.1 (HR=0.79)	(245)
MEDIOLA	Open label Phase II trial	PSROC Somatic BRCA mutation N=66	Olaparib + Durvalumab Olaparib + Durvalumab + Bevacizumab	31.3	5.5	26.1	(246, 247)
				77.4	14.7	31.9
TOPACIO	Open label, Phase I/II trial	Relapsed OC N=62	Niraparib + Pembrolizumab	18	3.4		(148)
DUO-O	Randomized, double-blind, phase III trial	Treatment naïve OC N=1104	Carboplatin doublet + bevacizumab + durvalumab + placebo	NA	20.6		(248)
			Carboplatin doublet + bevacizumab + durvalumab + olaparib	NA	24.2
MOCCA	Randomized, open-label, phase II trial	Relapsed OCCC <4 prior lines	Durvalumab	10.7	1.9	NA	(249)
PEACOCC	Open-label, single arm, phase II trial	Relapsed OCCC ≥1 prior line	Pembrolizumab	25	3.1	17.8	(250)

NA, Not Reached.